Evidence map›Paper›PMID 32246128›Full record

ReviewNature reviews. Clinical oncology2020

Moving towards personalized treatments of immune-related adverse events.

Khashayar Esfahani, Arielle Elkrief, Cassandra Calabrese, Réjean Lapointe, Marie Hudson, Bertrand Routy, Wilson H Miller, Leonard Calabrese

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed, 10 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 10 syntheses or guidelines pooled it, 331 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors.Neurology(R) neuroimmunology & neuroinflammation · 2021
    Pooled it
  10. Guideline
  11. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Khashayar EsfahaniDepartment of Medicine, Division of Oncology, McGill University, Montreal, Quebec, Canada. khashayar.esfahani@mail.mcgill.ca.ORCID http://orcid.org/0000-0003-2221-3755
Arielle ElkriefDepartment of Medicine, Division of Oncology, McGill University, Montreal, Quebec, Canada.
Cassandra CalabreseDepartment of Immunology and Rheumatology, Cleveland Clinic, Cleveland, OH, USA.
Réjean LapointeDepartment of Medicine, Centre de Recherche du Centre Hospitalier de l'Université de Montréal and Institut du Cancer de Montréal, Montreal, Quebec, Canada.
Marie HudsonDepartment of Medicine, Division of Rheumatology, McGill University, Montreal, Quebec, Canada.
Bertrand RoutyDepartment of Medicine, Centre de Recherche du Centre Hospitalier de l'Université de Montréal and Institut du Cancer de Montréal, Montreal, Quebec, Canada.
Wilson H MillerDepartment of Medicine, Division of Oncology, McGill University, Montreal, Quebec, Canada.
Leonard CalabreseDepartment of Immunology and Rheumatology, Cleveland Clinic, Cleveland, OH, USA.
McGill University · CACentre Hospitalier de l’Université de Montréal · CACleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour immune surveillance, but often at the expense of immune-related adverse events (irAEs). This novel disease entity often prompts comparisons with, and extrapolation of treatment approaches from, primary autoimmune disorders. Accordingly, current treatment guidelines for irAEs make generic recommendations adapted from the literature describing primary autoimmune diseases, without taking into consideration the substantial disparity of the immunohistopathological findings within each organ affected by an irAE. The treatment modalities themselves are complex and have many potential drawbacks, such as serious and rarely fatal infections, drug toxicities overlapping with irAEs and the risk of compromising cancer immune surveillance. Herein, we provide an overview of key cellular and soluble immunological factors mediating irAEs and propose a model integrating this knowledge with the immunohistopathological findings of the affected organs for a personalized decision-making process for each patient.

Indexed as

ImmunotherapyAntineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsHumansImmunologic FactorsImmunologic SurveillanceNeoplasmsAntineoplastic Agents, ImmunologicalImmunologic Factors

Identifiers

PMID32246128
OpenAlexW3015154527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.